
Conference Coverage
18 days ago
Elevate-Derm Summer Clinical PearlsLatest News
Videos

Shorts










Dermatology Times Digital Edition









All News

A pediatric dermatologist explains how CALM count, size, age, and associated findings separate benign spots from neurofibromatosis type 1 and its mimics.

At a Dermatology Times Case-Based Roundtable, Vishal A. Patel, MD, led a discussion on treatment selection, tolerability, and individualized care for patients with advanced basal cell carcinoma.

Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.

October brought FDA approvals in urticaria and HSV, new regulatory filings, and phase 3 advances in HS, psoriasis, and rare diseases.

Gaurav Singh, MD, MPH, FACMS, explores how gene expression profiling may improve melanoma risk stratification, surveillance, and individualized care.

A 2026 study links Agent Orange exposure to higher odds of acral melanoma in US veterans, highlighting the importance of early detection.

Phase 2 BEACON findings published in JAMA Dermatology demonstrate rapid improvements in disease activity and skin-related quality of life with oral brepocitinib.

Phase 2 AMETHYST findings show continued improvements in skin redness and clinician- and patient-reported outcomes with litifilimab.

Phase 2/3 data show sustained hair growth and favorable safety outcomes with oral VDPHL01 in men with androgenetic alopecia.

BE BOLD Week 24 data show sustained numerical advantages in joint responses with bimekizumab versus risankizumab in active psoriatic arthritis.

A single subcutaneous dose led to a 4-point or greater itch reduction in 82% of patients with chronic pruritus at week 12 vs 22% with placebo, Attovia reported.

At a Dermatology Times Case-Based Roundtable event, Carolyn Goh, MD, led clinicians through a discussion of severity scoring, patient-reported outcomes, CYP2C9 testing, and long-term monitoring across 3 alopecia areata cases.

The AADA warns that dermatologists could face a 6% Medicare payment reduction in 2027 despite CMS revisions to modifier 25 policies.

Pediatric dermatologists outline how to evaluate suspected topical steroid withdrawal, exclude mimics, and preserve family trust in eczema care.

Diego Ruiz Dasilva, MD, and Lindsey Finklea, MD, discuss the burden of chronic inducible urticaria and phase 3 remIND findings for remibrutinib.





























